CONBA(SH:600572) 智通财经网·2026-02-04 09:18Core Viewpoint - Kangnbei (600572.SH) has received approval from the National Medical Products Administration for the clinical trial of TFA003 tablets, which are intended for the treatment of diabetic kidney disease [1] Company Summary - Kangnbei's wholly-owned subsidiary, Hangzhou Kangnbei Pharmaceutical Co., Ltd., has been granted the Clinical Trial Approval Notice for TFA003 tablets [1] - The approval indicates that TFA003 tablets meet the requirements for drug registration as per the Drug Administration Law of the People's Republic of China [1] - The clinical trial is set to proceed after further refinement of the clinical trial protocol [1] Industry Summary - The approval of TFA003 tablets aligns with the growing focus on treatments for diabetic kidney disease, a significant health concern [1] - The development of new therapies in this area may enhance competition and innovation within the pharmaceutical industry [1]